FINTEPLA sol 2.2 mg/ml buvable fl 360 ml

7680693710023 CH-69371 N03AX26 01.07.1.
FINTEPLA sol 2.2 mg/ml buvable fl 360 ml
FINTEPLA sol 2.2 mg/ml buvable fl 360 ml
FINTEPLA sol 2.2 mg/ml buvable fl 360 ml
1 / 3
google

Details

Product number
6937101
CPT
-
Packaging group
360 ml
Unit
Flasche(n)
Composition
fenfluraminum 2.2 mg ut fenfluramini hydrochloridum, E 219 2.3 mg, E 215 0.23 mg, sucralosum, hydroxyethylcellulosum cum natrii dihydrogenophosphas et dinatrii phosphas, kalii citras, acidum citricum monohydricum, aromatica cerise cum glucosum, ethylis benzoas, maltodextrinum et E 220, aqua ad iniectabile ad solutionem pro 1 ml corresp. natrium 0.33 mg.

Articles (1)

Fintepla 2.2 mg/ml, solution buvable
Lösung
360 ml
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
17/10/2025
Patient information leaflet
Français
17/10/2025
Patient information leaflet
Italien
17/10/2025
Professional SmPC
Allemand
17/10/2025
Professional SmPC
Français
17/10/2025
Professional SmPC
Italien
17/10/2025

Detailed composition

Substance Quantity Type Category
(N/A)
2.2 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
2.3 MG Substance HBESI
(N/A)
0.23 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance AROMA
(N/A)
- Substance HBESI
(N/A)
- Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
0.33 MG Substance HBESI

Authorization holder

UCB-Pharma SA

1630 Bulle

Authorization information

Swissmedic authorization number
69371
Drug name
Fintepla, solution buvable
Galenic form
LSOR
ATC Code
N03AX26
Authorization status
Z
Dispensation category
A
First authorization
13/02/2025
Authorization expiration date
12/02/2030
IT number
01.07.1.
Domain
Human medicine
Field of application
Zusatztherapie bei Krampfanfällen in Zusammenhang mit dem Dravet-Syndrom (DS) oder dem Lennox-Gastaut-Syndrom (LGS), bei Patienten ab 2 Jahren

Packaging details

Description (FR)
FINTEPLA sol 2.2 mg/ml buvable fl 360 ml
Description (DE)
FINTEPLA Lös 2.2 mg/ml zum Einnehmen Fl 360 ml
Market launch
13/02/2025
Narcotic (BTM)
No

Other packaging sizes

FINTEPLA sol 2.2 mg/ml buvable fl 120 ml
120 ml FLAS
View